Pharmacological agents targeting NRF2 such as dimethyl fumarate have been employed for treating multiple sclerosis and psoriasis, and bardoxolone methyl has entered clinical phase II/III trials for treating CTD-PAH, pulmonary hypertension-ILD, Alport syndrome, and autosomal dominant polycystic kidney disease [19]. The gene discussed is NFE2L2; the disease is pulmonary arterial hypertension.